Toulose, France Clinical Trials

A listing of Toulose, France clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 130 clinical trials
Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: My Own Specific Treatment

The MOST Plus study is a two-period phase II clinical trial, conducted in patients with all types of progressive solid tumors after at least 1 prior systemic treatment regimen for advanced disease (in the absence of a validated second line therapy). The main goal of this study is to evaluate …

Institut Bergoni
 (131.0 away) Contact site
  • 0 views
  • 11 Feb, 2021
  • +11 other locations
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.

Centre L on B rard
 (222.8 away) Contact site
  • 272 views
  • 28 Jan, 2021
  • +75 other locations
A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension

The purpose of this study to confirm the selexipag starting dose(s), selected based on pharmacokinetic (PK) extrapolation from adults, that leads to similar exposure as adults doses in children from greater than or equal to (>=) 2 to less than () 18 years of age with Pulmonary Arterial Hypertension (PAH), …

heart disease
selexipag
endothelin receptor antagonist
connective tissue disease
hypertension
HOSP ARNAUD DE VILLENEUVE - PAED DEPT (Montpellier)
 (116.2 away) Contact site
  • 34 views
  • 18 Jul, 2021
  • +93 other locations
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

Institut Universitaire du Cancer de Toulouse Oncopole
 (0.5 away) Contact site
  • 50 views
  • 01 Apr, 2021
  • +122 other locations
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with …

Institut Claudius R gaud
 (0.5 away) Contact site
  • 2 views
  • 28 Jul, 2021
  • +77 other locations
A Safety Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

This is a phase 2 randomized, multi-center, double-blind, vehicle controlled, 90 day, safety, efficacy, and systemic exposure study followed by a 90 day open-label extension of trifarotene cream in adults and adolescents with autosomal recessive ichthyosis with lamellar scale.

Hospital Clinic de Barcelona
 (157.2 away) Contact site
  • 101 views
  • 12 Mar, 2021
  • +34 other locations
A Study of IMR-687 in Subjects With Beta Thalassemia

A Study to Evaluate the Safety and Tolerability of IMR-687 in Subjects with Beta Thalassemia

beta thalassemia
cell transplantation
Institut Universitaire du Cancer de Toulouse Oncopole
 (0.5 away) Contact site
  • 10 views
  • 10 Jun, 2021
  • +38 other locations
Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma

The primary objective of the study is to evaluate the efficacy of tislelizumab in participants with relapsed/refractory classical Hodgkin lymphoma, as measured by the overall response rate per the Lugano Classification, and as determined by the investigator.

avid
brentuximab
cancer
chemotherapy regimen
lymphoma
CHU de Montpellier
 (120.4 away) Contact site
  • 0 views
  • 28 Jun, 2021
  • +41 other locations
Safety Tolerability Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH)

The purpose of this study is to assess the effects of EYP001a with respect to safety, tolerability, pharmacokinetics and on markers of liver inflammation in patients with NASH

fibrosis
ENYO PHARMA Investigative site 0207
 (2.3 away) Contact site
  • 0 views
  • 24 Jan, 2021
  • +34 other locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

Institut Universitaire du Cancer Toulouse Oncopole
 (2.0 away) Contact site
  • 0 views
  • 15 Jul, 2021
  • +81 other locations